NCT07260851 Bioequivalence Study for the Safety and the Pharmacokinetics of DWJ1622, DWC202313, and DWC202314 in Healthy Volunteers Under Fasting Conditions
| NCT ID | NCT07260851 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Condition | Healthy Volunteers |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-11-05 |
| Primary Completion | 2026-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 40 participants in total. It began in 2025-11-05 with a primary completion date of 2026-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fasting conditions.
Eligibility Criteria
Inclusion Criteria: * Over 19 year old * Healthy adult volunteers Exclusion Criteria: * with a history of mental disorder * For female volunteers, those who are suspected of being pregnant or lactating
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07260851 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Healthy Volunteers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07260851 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07260851 currently recruiting?
Yes, NCT07260851 is actively recruiting participants. Contact the research team at hbshin028@daewoong.co.kr for enrollment information.
Where is the NCT07260851 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07260851 clinical trial?
NCT07260851 is sponsored by Daewoong Pharmaceutical Co. LTD.. The trial plans to enroll 40 participants.